The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

The "Osteoporosis_Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial report provides an overview of Osteoporosis Clinical ...

A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; ...

Interim Analysis Expected End of 2Q 2025BETHESDA, Md., March 14, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company ...

Persica's antibiotic-based drug could benefit patients with chronic lower back pain who are suffering from an infection in ...

LINCOLN, Neb.--(BUSINESS WIRE)--Celerion, a global leader in early clinical research, proudly announces a new agreement to relocate its U.K. Phase 1 clinical research operations to iREACH Health.

INDIA stands at a crossroads in the global clinical trials market. Despite its vast and diverse patient pool, cost-effective ...

Merck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...

PepGen has previously faced an FDA clinical hold on the investigational new drug application of PGN-ENO51 in the Phase II ...

Queen’s University Belfast has announced a new partnership with Celerion, a global leader in early clinical research. The agreement will see the US-headquartered company relocate its UK Phase 1 ...

Refractory chronic cough is a cough that persists for over 8 weeks and does not respond to treatment of any underlying cause. Recent randomised trials for refractory chronic cough have shown ...

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label ...